In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seres Therapeutics Inc.

www.serestherapeutics.com

Latest From Seres Therapeutics Inc.

Appointments: Astellas, MorphoSys, AZTherapies, Sigilon Therapeutics, Intec Pharma And Tenaya Therapeutics

This week's round-up includes promotions at Astellas, new CSOs at MorphoSys and Tenaya, a new president and CMO at AZTherapies, new directors at BioScience Managers, plus board changes at Intec and Sigilon.

Appointments BioPharmaceutical

Execs On The Move, August 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

Pipeline Watch: Phase III Starts For Seres' SER-109, Leo's Tralokinumab And Alkermes' ALKS-5461

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Expedited Review Pathways: Three More Breakthroughs, Third RMAT Awarded

US FDA's popular breakthrough therapy designation given to Proteon's vonapanitase for dialysis patients, Synthetic Biologics' ribaxamase to prevent C. difficile infection, and River Vision's teprotumumab for thyroid eye disease; Vericel's cell therapy for heart failure is designated a regenerative medicine advanced therapy.

Review Pathway Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Seres Health Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Seres Therapeutics Inc.
  • Senior Management
  • Roger Pomerantz, MD, Pres. & CEO
    Eric Shaff, EVP, CFO
    David Cook, PhD, EVP, R&D & CSO
    Shelly Trucksis, MD, PhD, EVP, CMO
  • Contact Info
  • Seres Therapeutics Inc.
    Phone: (617) 945-9626
    161 First St.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register